8-K/A: Pennant Group Expands Home Health & Hospice via Acquisitions

The Pennant Group filed an 8-K/A detailing the financial statements and pro forma impact of its recent acquisition of home health and hospice subsidiaries from Amedisys and UnitedHealth.

Summary

• Pennant Group (PNTG) completed the acquisition of home health, hospice, and palliative care service subsidiaries from Amedisys, Inc. and UnitedHealth Group Incorporated on October 1, 2025.
• The total estimated cash consideration for the transaction was approximately $149.0 million.
• The acquisition was financed by $146.5 million in new debt under Pennant's credit facility, supplemented by cash on hand.
• The acquired Amedisys subsidiaries reported $79.7 million in revenue and $14.5 million in revenue less direct expenses for the year ended December 31, 2024.
• The acquired UnitedHealth subsidiaries reported $104.3 million in revenue and $26.9 million in revenue less direct expenses for the year ended December 31, 2024.
• On a pro forma basis, Pennant's combined revenue for the year ended December 31, 2024, would have been $879.3 million, with net income attributable to Pennant Group of $38.4 million, and diluted EPS of $1.20.
• The pro forma combined revenue for the six months ended June 30, 2025, would have been $524.8 million, with net income attributable to Pennant Group of $26.1 million, and diluted EPS of $0.74.
• The financial statements for the acquired entities are abbreviated and exclude corporate overhead costs, meaning they are not fully indicative of future stand-alone results under Pennant's operation.
• A preliminary purchase price allocation has been made, with finalization expected within one year of the closing date.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the successful completion of a significant strategic acquisition that substantially increases Pennant's revenue and operational footprint in a growing healthcare sector. However, the preliminary nature of the financial allocations, the exclusion of corporate overhead from the acquired entities' historical financials, and the inherent integration risks temper the overall sentiment, warranting careful monitoring.

Positives

• Successful completion of a strategic acquisition significantly expanding Pennant's presence in the home health, hospice, and palliative care sectors.
• The acquired businesses demonstrate positive "Revenue less direct expenses" (a proxy for operating income before corporate overhead), indicating operational efficiency at the direct service level.
• Pro forma financial statements show a substantial increase in Pennant's total revenue and net income, enhancing its market position and scale.
• The acquisition diversifies Pennant's payor mix, with Medicare and managed care representing significant portions of revenue for the acquired entities.

Negatives

• The abbreviated financial statements for the acquired subsidiaries do not include corporate overhead costs, which Pennant will incur, making their historical "Revenue less direct expenses" not fully representative of future profitability.
• The financial information for the acquired entities is "carved-out" and may not reflect results had they operated as stand-alone entities.
• The purchase price allocation is preliminary and subject to material changes within one year of the closing date.
• The pro forma financial statements do not account for potential revenue enhancements, cost savings, operating synergies, or dis-synergies, nor do they include estimated transition service fees of approximately $1.0 million per month.

Risks

• The final acquisition accounting adjustments, including the fair values of assets and liabilities and purchase price allocation, may differ materially from the preliminary pro forma adjustments.
• The actual costs and operating results of the acquired subsidiaries under Pennant's management may differ from the historical abbreviated financials due to the exclusion of corporate overhead costs in the historical data.
• Uncertainty regarding the actual fees to be incurred during the transition service period under the agreement with the sellers.
• The blended statutory tax rate used in pro forma calculations may not be indicative of Pennant's actual effective tax rate post-transaction.
• Potential for material changes to the purchase price consideration based on final working capital and other adjustments.

Future Outlook

The filing states that the abbreviated financial statements are not indicative of future results as they omit various operating expenses Pennant will incur. It also notes that the pro forma statements do not give effect to potential revenue enhancements, cost savings, operating synergies, or dis-synergies that may result from the transaction. The final purchase price allocation is expected to be completed within one year of the October 1, 2025, closing date.

Industry Context

The acquisition of home health, hospice, and palliative care services aligns with the broader healthcare trend of providing care in lower-cost, patient-preferred settings, particularly for an aging population. This expansion strengthens Pennant's position in the post-acute care continuum, a growing segment of the healthcare industry.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through expanded market presence, higher revenue, and enhanced earnings capacity, though subject to successful integration and final financial outcomes.
• Employees: Employees of the acquired Amedisys and UnitedHealth subsidiaries are now part of The Pennant Group, potentially experiencing changes in corporate culture, benefits, and operational procedures.
• Customers (Patients): Continued provision of home health, hospice, and palliative care services, potentially benefiting from Pennant's operational model and resources.
• Creditors: Increased debt burden for Pennant Group due to the $146.5 million in new long-term debt, which will impact financial leverage and interest expense.

Next Steps

• Finalization of the detailed valuation procedures and purchase price allocation within one year of the October 1, 2025, closing date.
• Integration of the acquired home health, hospice, and palliative care services into Pennant's existing operations.
• Management of transition services agreement with sellers, with fees estimated at $1.0 million per month initially.

Key Dates

Recommendation

The acquisition represents a significant strategic expansion for Pennant Group into the growing home health and hospice market, substantially increasing its revenue and operational scale. While the pro forma financials indicate a positive impact on the company's top and bottom lines, the preliminary nature of the purchase price allocation and the exclusion of corporate overhead from the acquired entities' historical financials introduce a degree of uncertainty regarding the ultimate profitability and integration challenges. A seasoned investor would likely maintain a "hold" position to observe the successful integration of these assets, the finalization of acquisition accounting, and the realization of anticipated synergies before making a more aggressive "buy" recommendation. The increased debt also warrants monitoring.

Keywords

Healthcare services, Home health, Hospice, Palliative care, Acquisition, Merger, SEC filing, Financial statements, Pro forma, Pennant Group, Amedisys, UnitedHealth, Post-acute care, PNTG